Figure 1.

XPO1 is overexpressed in Luminal B breast cancers and targeting XPO1 modulates Akt signaling. (A) Verification of XPO-1 protein levels in patient tumor samples (BRC1021 from Pantomics, Inc containing 95 cases with known ER, PR, AR, Her2, p53, EGFR, and Ki67 IHC results). For each core, a score for XPO1 was assigned based on the signal intensity (0 = none, 1 = low, 2 = moderate, and 3 = high). (B) XPO1 staining intensity from (A). (C) Percentage of XPO1 positive cells from (A). (D) Isobologram analysis of synergy between 4-OHT and SEL in BT474 cells. (E) BT474 xenograft experiment showing that combined targeting of ERα and XPO1 provided sustained tumor regression. (Adapted from [11]). * p < 0.05, **** p < 0.0001